NICE IDs

06/03/2025

ID6130: Leniolisib for activated phosphoinositide 3-kinase delta syndrome in people 12 years and over

20/02/2025

ID6170: Efanesoctocog alfa for treating and preventing bleeding episodes in haemophilia A

17/02/2025

ID5123: Zolbetuximab with chemotherapy for untreated claudin 18.2-positive HER2 negative unresectable advanced gastric or gastro-oesophageal junction adenocarcinoma

17/02/2025

ID3982: Relugolix–estradiol–norethisterone for treating symptoms of endometriosis

30/01/2025

ID6405: Blinatumomab with chemotherapy for consolidation treatment of Philadelphia-chromosome-negative CD19-positive minimal residual disease-negative B-cell precursor acute lymphoblastic leukaemia

16/09/2024

ID5088: Danicopan as an add-on treatment to a C5 inhibitor for treating extravascular haemolysis in adults with paroxysmal nocturnal haemoglobinuria

12/09/2024

ID4042: Quizartinib for induction, consolidation and maintenance treatment of newly diagnosed FLT3-ITD-positive acute myeloid leukaemia

21/08/2024

ID6298: Trifluridine–tipiracil with bevacizumab for treating metastatic colorectal cancer after 2 systemic treatments

01/08/2024

ID6197: Faricimab for treating visual impairment caused by macular oedema after retinal vein occlusion

01/07/2024

ID6187: Relugolix for treating hormone-sensitive prostate cancer

31/05/2024

ID4025: Lebrikizumab for treating moderate to severe atopic dermatitis in people 12 years and over

24/04/2024

ID5104: Dabrafenib with trametinib for treating BRAF V600E mutation-positive glioma in children and young people aged 1 year and over

21/02/2023

ID4038: Therapeutics for people with COVID-19

11/10/2021

ID1334: Glasdegib with chemotherapy for untreated acute myeloid leukaemia

11/10/2021

ID2710: Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for moderate rheumatoid arthritis after conventional DMARDs have failed (partial review of TA375)

11/10/2021

ID1596: Ropeginterferon alfa-2b for treating polycythaemia vera without symptomatic splenomegaly

11/10/2021

ID1625: Nivolumab with cabozantinib for untreated advanced or metastatic renal cell carcinoma

11/10/2021

ID1631: Risdiplam for treating spinal muscular atrophy in children and adults

11/10/2021

ID1564: Venetoclax with a hypomethylating agent or low dose cytarabine for untreated acute myeloid leukaemia when intensive chemotherapy is unsuitable

11/10/2021

ID1609: Nivolumab with ipilimumab for untreated unresectable malignant pleural mesothelioma